Intratumoral PD-1+CD8+ T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer
Open Access
- 24 August 2022
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 127 (9) , 1709-1717
Abstract
Background: Although PD-1 has been reported to be a marker of T-cell exhaustion in several malignancies, the biological role of PD-1+CD8+ T cells in gastric cancer (GC) remains unclear. Herein, we aimed to investigate the role of PD-1+CD8+ T cells in the tumour microenvironment and its clinical significance in GC. Designs: This study included 441 tumour microarray specimens and 60 Flow cytometry specimens of GC patients from Zhongshan Hospital, and 250 GC patients from the Asian Cancer Research Group. Results: Here, we demonstrated that PD-1+CD8+ T cells functioned as an independent adverse prognosticator in GC. In addition, an abundance of intratumoral PD-1+CD8+ T cells indicated worse chemotherapeutic responsiveness to fluorouracil in Stage III GC patients. Mechanistically, PD-1+CD8+ T cell high infiltration indicated an exhausted phenotype of global CD8+ T cells in GC tissues, which was characterised by elevated immune checkpoint expression including CTLA-4 and TIM-3, whereas decreased expression of perforin. Furthermore, PD-1+CD8+ T cell high-infiltration patients with Stage III GC held elevated activity of several therapeutic signal pathways. Conclusions: Our study highlighted that PD-1+CD8+ T cell abundance predicts inferior prognosis in GC, and may serve as a novel predictive biomarker to guide therapeutic option.Keywords
This publication has 37 references indexed in Scilit:
- Global cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2015
- PD-1+ CD8+ T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patientsBritish Journal of Cancer, 2014
- Comprehensive molecular characterization of gastric adenocarcinomaNature, 2014
- Adjuvant therapy for gastric cancer after D2 gastrectomyThe Lancet, 2012
- Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric CancerJournal of Clinical Oncology, 2011
- Roles of inflammatory cytokines in the progression of gastric cancer: friends or foes?Gastric Cancer, 2010
- Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trialThe Lancet Oncology, 2010
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007
- 5-Fluorouracil: mechanisms of action and clinical strategiesNature Reviews Cancer, 2003
- Gastric CarcinomaNew England Journal of Medicine, 1995